Overview
- Musk announced on X that Neuralink will pursue high‑volume device production in 2026 and an almost fully automated surgery that he says will place threads through the dura without removing it.
- Neuralink says 12 people with severe paralysis had received implants by September 2025 and were actively using them to control computers and other tools.
- The company’s regulatory path included an FDA rejection in 2022, clearance for human trials in 2024, and a 2025 approval for a speech‑restoration device indication.
- Neuralink raised $650 million in a June 2025 Series E round, reporting a valuation near $9 billion to support manufacturing scale‑up.
- The company touts a next‑generation robot that inserts electrode threads in about 1.5 seconds per thread and reports initial procedures outside the U.S., including in Canada and the U.K.